The prevalence of Aβ and p-Tau pathology among PWH indicates the importance of utilizing multiple AD-associated clinical and biological markers in order to differentiate healthy aging from an AD trajectory among PWH. This evidence concerns the gene MAPT and Alzheimer disease.